Description: Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
Home Page: www.dynavax.com
0IDA Technical Analysis
2100 Powell Street
EmeryVille,
CA
94608
United States
Phone:
510 848 5100
Officers
| Name | Title |
|---|---|
| Mr. Ryan Spencer | CEO & Director |
| Mr. David F. Novack | President & COO |
| Ms. Kelly MacDonald CPA | Senior VP & CFO |
| Dr. Robert Janssen M.D. | Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs |
| Mr. Justin Burgess | Chief Accounting Officer & Controller |
| Mr. Jeff P. Coon | Senior VP & Chief Human Resources Officer |
| Mr. Paul Cox | VP of Investor Relations & Corporate Communications |
| Mr. John L. Slebir | Senior VP & General Counsel |
| Mr. Donn Casale | Senior VP & Chief Commercial Officer |
| Dr. Dong Yu | Senior Vice President of Research |
Exchange: LSE
Country: GB : United Kingdom of Great Britain and Northern Ireland
Currency: US Dollar ($)
| GIC Sector: | Industrials |
|---|---|
| GIC Group: | Commercial & Professional Services |
| GIC Industry: | Commercial Services & Supplies |
| GIC Sub-Industry: | Environmental & Facilities Services |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.174 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 1.0639 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 408 |